These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19680291)

  • 21. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
    Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
    Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.
    Kani K; Sordella R; Mallick P
    Methods Mol Biol; 2012; 795():233-53. PubMed ID: 21960227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel targeted therapies for non-small cell lung cancer.
    Smith PW; Denlinger CE; Jones DR
    Thorac Surg Clin; 2006 Nov; 16(4):353-66. PubMed ID: 17240823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer.
    Jalal SI; Ademuyiwa FO; Hanna NH
    Curr Opin Oncol; 2009 Mar; 21(2):110-5. PubMed ID: 19532011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
    Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
    Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
    McDermott U; Settleman J
    J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor as a target in cancer therapy.
    Kim ES
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The biology of non-small-cell lung cancer: identifying new targets for rational therapy.
    Rosell R; Felip E; Garcia-Campelo R; Balaña C
    Lung Cancer; 2004 Nov; 46(2):135-48. PubMed ID: 15474661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Target population and predictive factors of survival and efficacy of anti-HER1/EGFR drugs].
    Cadranel J
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S10-1. PubMed ID: 17242637
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
    Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
    Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
    Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
    Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
    Gadgeel SM
    Adv Exp Med Biol; 2016; 890():203-22. PubMed ID: 26703806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?
    Martinez P; Martinez-Marti A; Navarro A; Cedrés S; Felip E
    Lung Cancer; 2014 May; 84(2):97-100. PubMed ID: 24582269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy for lung cancer: the state of the art in 2009.
    Higgins MJ; Ettinger DS
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1365-78. PubMed ID: 19827996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second and third line treatment in non-small cell lung cancer.
    Favaretto A; Pasello G; Magro C; Schettino C; Gridelli C
    Crit Rev Oncol Hematol; 2009 Aug; 71(2):117-26. PubMed ID: 19249227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of unfit older patients with advanced NSCLC.
    Gridelli C; Maione P; Rossi A; Palazzolo G; Colantuoni G; Rossi E
    Cancer Treat Rev; 2009 Oct; 35(6):517-21. PubMed ID: 19457617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.